$VTGN climbs on preliminary positive data from the PALISADE-4 open-label extension.
Symbol-specific history of its gap-up sessions shows 67 percent close below the open across 24 prior cases.
The extension phase measures tolerability, not yet the registrational endpoint.
Also on the tape: #GCDT +37% (1-for-6 consolidation), #CTNT -23% (rights modification filing).